Personalized Cancer Treatment System with Targeted Fusion Protein and Anticancer Agent

A next-generation cancer treatment system that combines a genetically engineered fusion protein dimer with a tailored anticancer agent, providing a personalized and targeted approach to cancer therapy.

The original patent disclosed a pharmaceutical composition for cancer treatment comprising a fusion protein dimer and an anticancer agent. However, this composition has limitations in terms of its generic approach to cancer treatment, lacking the ability to target specific cancer cells based on their genetic profile. The new inventive concept addresses this limitation by engineering the fusion protein dimer to target specific cancer cells and tailoring the anticancer agent to the specific genetic profile of the cancer cells.

The new inventive concept consists of a system for personalized cancer treatment, comprising a fusion protein dimer engineered to target specific cancer cells based on their genetic profile, and an anticancer agent tailored to the specific genetic profile of the cancer cells. The fusion protein dimer is designed to bind specifically to cancer cells with a particular genetic mutation, allowing for targeted delivery of the anticancer agent. The anticancer agent is selected based on the genetic profile of the cancer cells, ensuring maximum efficacy and minimal side effects. The system also includes a method for real-time monitoring of cancer treatment, allowing for adjustments to the dosage of the anticancer agent as needed.

The new inventive concept is novel and non-obvious compared to the original patent, as it introduces a personalized and targeted approach to cancer treatment, using genetically engineered fusion protein dimers and tailored anticancer agents. The inventive step lies in the engineering of the fusion protein dimer to target specific cancer cells and the tailoring of the anticancer agent to the specific genetic profile of the cancer cells.

Alternative embodiments of the inventive concept could include the use of different types of fusion protein dimers, such as those engineered to target specific cancer stem cells or those conjugated to nanoparticles for targeted delivery. Variations could also include the use of different types of anticancer agents, such as immunotherapies or gene therapies.

The new inventive concept has significant commercial potential in the field of cancer treatment, with a target market including pharmaceutical companies, hospitals, and research institutions. The system's ability to provide personalized and targeted cancer treatment could revolutionize the field of oncology, offering a more effective and efficient approach to cancer therapy.